TetraLogic Pharmaceuticals Corporation (TLOG)

Market Cap	24.00 -99.5%
Revenue (ttm)	n/a
Net Income	-40.72M
EPS	-1.65
Shares Out	24.32M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,016
Open	0.000001
Previous Close	n/a
Day's Range	0.000001 - 0.000001
52-Week Range	0.000001 - 0.0002
Beta	-73.59
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About TLOG

TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells. SHAPE is its proprietary histone deacetylase inhibitor for topical use for the treatment of early-stage cuta...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 8
• Stock Exchange: OTCMKTS
• Ticker Symbol: TLOG

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 18, 2026

Data Sources Report a data error